eTheRNA Immunotherapies To Present At Sachs Biotech In Europe Forum

Published: Sep 21, 2017

Niel (Belgium), 21 September 2017 – eTheRNA immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces that its CEO Dirk Reyn is to present an overview of the company, its novel technologies and development pipeline at the Sachs 17th Biotech in Europe Forum for Global Partnering and Investment.

The presentation will take place on 27 September at 12:15pm in Presentation Track C, which takes place at the Congress Center, Basel, Switzerland.

The Sachs Biotech in Europe Forum for Global Partnering and Investment is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. The forum brings together a cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. More than 600 delegates are expected to attend.


Dirk Reyn, CEO

Tel: +32 3 369 17 40
Media Relations
Citigate Dewe Rogerson
David Dible, Mark Swallow, Pip Batty
Tel: +44 (0)20 7638 9571

About eTheRNA

eTheRNA intends to become a leading cancer-focused mRNA immunotherapy company by developing and commercializing rationally designed mRNA immunotherapies that deliver long-lasting clinical remission to a broad range of cancer patients.

eTheRNA’s products are based on its unique TriMix platform, a combination of three mRNAs encoding proteins that act highly synergistically to activate dendritic cells (DCs), a type of dedicated immune cell also known as an antigen presenting cells (APC), to promote enhanced T-cell immunity. In combination with mRNA coding for tumor-specific antigens, TriMix products can also promote an antigen-directed cytotoxic T-cell response.

The Company has already generated compelling clinical data from initial TriMix ex-vivo candidates, paving the way for the clinical development of TriMix in-vivo mRNA immunotherapies, which are administered intranodally or intratumorally. The Company has also generated strong pre-clinical data showing the effectiveness of TriMix in-vivo immunotherapies in multiple cancer models.

eTheRNA believes its TriMix platform has the potential to provide cancer patients with better clinical outcomes and is committed to establish its unique technology as the gold standard in the wider area of immune-oncology – both as a monotherapy and in combination with other cancer therapies.

eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is backed by leading international life sciences investors since March 2016.

Back to news